87 related articles for article (PubMed ID: 17050794)
21. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.
Hägg S; Spigset O; Dahlqvist R
Br J Clin Pharmacol; 2001 Feb; 51(2):169-73. PubMed ID: 11259990
[TBL] [Abstract][Full Text] [Related]
22. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation.
Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
Mutagenesis; 2005 Mar; 20(2):93-100. PubMed ID: 15728263
[TBL] [Abstract][Full Text] [Related]
23. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
24. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s.
Narimatsu S; Takemi C; Kuramoto S; Tsuzuki D; Hichiya H; Tamagake K; Yamamoto S
Chirality; 2003 May; 15(4):333-9. PubMed ID: 12666241
[TBL] [Abstract][Full Text] [Related]
25. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.
Becquemont L; Chazouilleres O; Serfaty L; Poirier JM; Broly F; Jaillon P; Poupon R; Funck-Brentano C
Clin Pharmacol Ther; 2002 Jun; 71(6):488-95. PubMed ID: 12087352
[TBL] [Abstract][Full Text] [Related]
26. Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis.
Kennedy MJ; Scripture CD; Kashuba AD; Scott CS; Gaedigk A; Kearns GL
Clin Pharmacol Ther; 2004 Mar; 75(3):163-71. PubMed ID: 15001967
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
[TBL] [Abstract][Full Text] [Related]
28. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline.
Baumann P; Meyer JW; Amey M; Baettig D; Bryois C; Jonzier-Perey M; Koeb L; Monney C; Woggon B
Ther Drug Monit; 1992 Feb; 14(1):1-8. PubMed ID: 1546384
[TBL] [Abstract][Full Text] [Related]
29. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
[TBL] [Abstract][Full Text] [Related]
30. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
31. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.
Tracy TS; Venkataramanan R; Glover DD; Caritis SN;
Am J Obstet Gynecol; 2005 Feb; 192(2):633-9. PubMed ID: 15696014
[TBL] [Abstract][Full Text] [Related]
32. Studies on the metabolic fate of M17055, a novel diuretic (6). Assessment for drug-drug interactions of M17055 in metabolism, distribution and excretion.
Nakajima H; Nakanishi T; Naba H; Nakai K; Matsumoto S; Nagasawa K; Ida K; Ogihara T; Ohzawa N
Xenobiotica; 2002 Dec; 32(12):1161-72. PubMed ID: 12593763
[TBL] [Abstract][Full Text] [Related]
33. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
[TBL] [Abstract][Full Text] [Related]
34. The action of cytochrome b(5) on CYP2E1 and CYP2C19 activities requires anionic residues D58 and D65.
Peng HM; Auchus RJ
Biochemistry; 2013 Jan; 52(1):210-20. PubMed ID: 23193974
[TBL] [Abstract][Full Text] [Related]
35. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450-mediated biotransformation (a corrigendum report on Duarte et al. (2005) Mutagenesis 20, 93-100).
Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
Mutagenesis; 2007 Jan; 22(1):75-81. PubMed ID: 17158518
[TBL] [Abstract][Full Text] [Related]
36. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Adedoyin A; Arns PA; Richards WO; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1998 Jul; 64(1):8-17. PubMed ID: 9695714
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity.
Matzke GR; Frye RF; Early JJ; Straka RJ; Carson SW
Pharmacotherapy; 2000 Feb; 20(2):182-90. PubMed ID: 10678296
[TBL] [Abstract][Full Text] [Related]
38. Omega-hydroxylation of farnesol by mammalian cytochromes p450.
DeBarber AE; Bleyle LA; Roullet JB; Koop DR
Biochim Biophys Acta; 2004 Jun; 1682(1-3):18-27. PubMed ID: 15158752
[TBL] [Abstract][Full Text] [Related]
39. Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer.
Romkes M; Chern HD; Lesnick TG; Becich MJ; Persad R; Smith P; Branch RA
Carcinogenesis; 1996 May; 17(5):1057-62. PubMed ID: 8640913
[TBL] [Abstract][Full Text] [Related]
40. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.
Koch KM; Corrigan BW; Manzo J; James CD; Scott RJ; Stead AG; Kersey KE
Aliment Pharmacol Ther; 2004 Jul; 20(2):223-30. PubMed ID: 15233703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
